Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice

Andrew N. Fleischman, Osheiza Abdulmalik(Children's Hospital of Philadelphia), R. Clark Brown(Chrysalis BioTherapeutics (United States)), Kandace Gollomp(Children's Hospital of Philadelphia), David R. Light(Thermo Fisher Scientific (Norway)), Conroy O. Field(Children's Hospital of Philadelphia), Benita Balogun(Children's Hospital of Philadelphia), Martin K. Safo(Virginia Commonwealth University)
Blood
November 3, 2025
10.1182/blood-2025-2932
Cited by 1

Related Papers

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells
|Science|2018|159